| Info Sheets |
| | | | | | | | | | | | | | | | | | | | | | | | |
| Out- side |
| | | | |
|
| | | | |
Result : Searchterm 'MultiHance' found in 1 term [] and 8 definitions []
| previous 6 - 9 (of 9) Result Pages : [1] [2] | | | | Searchterm 'MultiHance' was also found in the following service: | | | | |
| | |
| |
|
(Gd) Gadolinium is a Lanthanide element that is paramagnetic in its trivalent state.
This paramagnetic substance is used for MR imaging because of the effect of strongly decreasing the T1 relaxation times of the tissues to which gadolinium has access. When injected during magnetic resonance imaging, gadolinium will tend to change signal intensities by shortening the T1 time in its surroundings.
The relaxivity of gadolinium is an important measure of its efficacy, which is dependent on the chemical properties of the complex. The gadolinium ion cannot be used in its chloride, sulfate, or acetate forms because of poor tolerance and low solubility in water in the neutral pH range. Although toxic by itself, gadolinium can be given safely in a chelated form such as DTPA, that still retains much of its strong effect on relaxation times ( relaxivity).
See also Dotarem®, Gadovist®, MultiHance®, Omniscan®, OptiMARK®, and Contrast Agents, the info sheet gives an overview and more in-dept information about different types of MRI contrast agents. | | | | | | | | | | | Further Reading: | | Basics:
|
|
News & More:
| |
| |
| | | | | |
| |
|
Macromolecular Gd labeled albumins are a new class of contrast agents with a wide range of use e.g., MR angiography, breast MRI, perfusion MRI, Lung perfusion, etc.
Marketed gadolinium-based albumin-bound contrast media are e.g., MultiHance®, and Vasovist™; other prototypes are in development.
Malignant tumors often show an increased uptake and metabolism of plasma proteins, especially albumin. Contrast agents with large molecules are delivered to all tissues, but only accumulate in those with leaky vessels by tumor capillaries (tumor neovessels). MRI tumor perfusion studies with Gd labeled albumin can show the success of tumor therapy by quantitative decrease in MR signal of the malignant tissue after therapy compared to before.
In addition, the study of tumor sensitivity to a therapy with drug-labeled albumins seems possible.
After renal transplantation, MRI may diagnose albuminuria caused by glomerular disease with an albumin-bound blood pool contrast agent
See also Blood Pool Agents, Intravascular Contrast Agents, Contrast Enhanced MRI. | | | | • View the DATABASE results for 'Gd Labeled Albumin' (2).
| | | | Further Reading: | Basics:
|
|
News & More:
| |
| |
| | | | | |
| |
|
| | | | • View the DATABASE results for 'Hepatobiliary Chelates' (6).
| | | | |
| | | Searchterm 'MultiHance' was also found in the following service: | | | | |
| | |
| |
|
Magnetic relaxation in tissues can be enhanced using contrast agents. The most commonly used for MRI are the paramagnetic contrast agents, which have their strongest effect on the T1, by increasing T1 signal intensity in tissues where they have accumulated.
MRI collects signal from the water protons, but the presence of these contrast agents enhances the relaxation of water protons in their vicinity.
Paramagnetic contrast agents contain magnetic centers that create magnetic fields approximately one thousand times stronger than those corresponding to water protons. These magnetic centers interact with water protons in exactly the same way as the neighboring protons, but with much stronger magnetic fields, and therefore, have a much greater impact on relaxation rates, particularly on T1. In MRI, contrast agents are routinely injected intravenously to help identify areas of hypervascularity, as in malignant tumors.
See also Contrast Agents, Gadovist®, MultiHance®, Omniscan®, OptiMARK®.
See also the related poll result: ' The development of contrast agents in MRI is' | | | | | | • View the DATABASE results for 'Paramagnetic Contrast Agents' (22).
| | | • View the NEWS results for 'Paramagnetic Contrast Agents' (1).
| | | | Further Reading: | Basics:
|
|
News & More:
| |
| |
| | | | |
| | | |
|
| |
| Look Ups |
| |